Table 2
From: TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
Primary Antibody | Vendor | Catalog number | Dilution |
ERG 1/2/3 | Santa Cruz Biotechnology | sc-28,680 | 1:5000 |
AR (N-20) | Santa Cruz Biotech | sc-816 | 1:1000 |
GAPDH | Santa Cruz Biotech | sc-25,778 | 1:10000 |
AKR1C3 | Sigma Aldrich | A6229 | 1:1000 |
HSD3B1 | Sigma Aldrich | WH0003283M1 | 1:1000 |
HSD3B2 | Sigma Aldrich | SAB1402232 | 1:1000 |
Secondary Antibody | Vendor | Catalog number | Dilution |
Anti-rabbit IgG, HRP | Cell Signaling Technology | 7074S | 1:5000 |
Anti-mouse IgG, HRP | Cell Signaling Technology | 7076S | 1:5000 |